文献速递泌尿生殖腹部MR

前列腺癌的影像学T分期:迈向通用的基于MRI的评分系统

Radiological T-staging in prostate Cancer: Towards a universal MRI-based scoring system.
PubMed 文献 · Eur J Radiol · 2025-08-14

本文为叙述性综述,批判性审视当前基于MRI的前列腺癌局部T分期性能、局限性及影像评分系统的临床意义。文章强调从定性评估向半定量和定量系统演变,这些系统整合肿瘤包膜接触长度、膨隆、包膜不规则、神经血管束不对称和包膜强化等特征。新兴数据显示肿瘤体积和曲线包膜接触长度具有高特异度,但多数特征缺乏足够敏感度和读者间一致性以独立指导治疗管理。作者主张在MRI T分期中优先考虑特异度而非敏感度,并提出开发面向临床相关性的通用MRI评分系统。

要点

  • MRI区分器官局限(T2)与局部进展(T3a)肿瘤的准确度仍低。
  • 肿瘤体积和曲线包膜接触长度显示高特异度,但多数特征敏感度和读者间一致性不足。
  • 作者主张MRI T分期优先特异度而非敏感度,以减少假阳性导致的过度治疗。

核心结论

  • 作者主张在MRI T分期中优先特异度而非敏感度,并提议开发面向临床相关性的通用MRI评分系统,以提供可重复的治疗决策指导,减少过度治疗及其副作用,促进临床试验和实践中的标准化报告。

研究设计与样本

  • 叙述性综述,批判性审视当前基于MRI的前列腺癌局部T分期性能、局限性及影像评分系统的临床意义。

诊断标准与关键数值

  • 定性评估向半定量和定量系统演变,整合肿瘤包膜接触长度、膨隆、包膜不规则、神经血管束不对称和包膜强化等特征。
  • 新兴数据显示肿瘤体积和曲线包膜接触长度具有高特异度。
  • 多数特征缺乏足够敏感度和读者间一致性以独立指导治疗管理。

临床应用与阅片要点

  • 作者主张在MRI T分期中优先特异度而非敏感度,考虑假阳性MRI读数对患者后续过度治疗带来负面副作用。
  • 作者提议开发面向临床相关性的通用MRI评分系统,优先提供可重复的治疗决策指导而非传统分期准确度。

局限性

  • 多数特征缺乏足够敏感度和读者间一致性以独立指导治疗管理。
  • MRI区分器官局限(T2)与局部进展(T3a)肿瘤的准确度仍低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Magnetic resonance imaging (MRI) is recommended for local prostate cancer tumor (T) staging. While MRI offers superior anatomical resolution compared to digital rectal examination, its accuracy in distinguishing organ-confined (T2) from locally advanced (T3a) tumors remains low. This narrative review critically examines the current MRI-based T-staging performance, its limitations, and the clinical implications of image scoring systems to assess local tumor extent. We highlight the evolution from qualitative assessments toward semi-quantitative and quantitative systems, each integrating features like tumor capsular contact length, bulging, capsular irregularity, neurovascular bundle asymmetry, and capsular enhancement. Emerging data suggest that tumor volume and curvilinear capsular contact length exhibit high specificity, however, most features lack sufficient sensitivity and inter-reader agreement to independently guide treatment management. We argue for favoring specificity over sensitivity in MRI-based T-staging, considering that false positive MRI readings carry negative side effects for patients following overtreatment. Finally, we propose the development of a universal MRI-based scoring system tailored to clinical relevance, prioritizing reproducible guidance for treatment decisions over traditional staging accuracy. Such a scoring system better aligns with contemporary therapeutic goals, reduces overtreatment with its negative side effects, and facilitates standardized reporting in clinical trials and practice.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Agrotis G, Woo S, Jäderling F, et al. Radiological T-staging in prostate Cancer: Towards a universal MRI-based scoring system. Eur J Radiol. 2025. PMID: 40834651. doi:10.1016/j.ejrad.2025.112363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。